FDA accepts Takeda's biologics license application for ulcerative colitis drug

The FDA accepted Takeda's application for an injectable version of its ulcerative colitis drug Entyvio.

If approved, vedolizumab — marketed as Entyvio — will be available in prefilled syringe and pen options.

Takeda based its application on its Visible 1 phase 3 study. In it, a significant proportion of patients treated with Entyvio achieved clinical remission compared to those receiving a placebo.

Takeda GI Business Unit senior vice president Uthra Sundaram said, "The availability of a subcutaneous option for maintenance therapy with vedolizumab, in addition to the currently approved intravenous formulation, would provide physicians and patients with greater flexibility on route of administration, if approved."

More articles on gastroenterology:
Healthcare experts discuss investor interest in orthopedics — 5 key points
University of Maryland children's medical device competition reveals 5 winners
RTI Surgical reports $9.1M net loss in Q1: 5 details

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months